In this study, we presented evidence to demonstrate frequent genetic alterations in ATM and TP53 genes in most R/R patients with MCL, including those with intrinsic or acquired resistance to ibrutinib or CD19-targeted CAR T-cell therapy. The gene discussed is CD19; the disease is mantle cell lymphoma.